Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Section 4 of 6

Clinical evidence

329 evidence topics · 58 sources

Study summaries

Integrated externally controlled survival analysis

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using overall survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Company-presented survival analysis with broader external controls: prespecified subgroup analyses
Company-presented survival analysis with broader external controls: sensitivity analyses
Results
Participant disposition
Baseline characteristics
Company-presented survival analysis with broader external controls: baseline characteristics of 72 treated and 119 matched controls
CharacteristicAdrabetadex (N=72)External control (N=119)
Age at onset under 2 years, n/N (%)“32/72 (44)”“57/119 (48)”
Age at onset 2 to under 6 years, n/N (%)“40/72 (56)”“62/119 (52)”
Median age at neurological onset, months (Q1, Q3)“25 (0, 68)”“24 (0, 68)”
Overall miglustat use, n/N (%)“52/72 (72)”“72/119 (61)”
Gastrostomy tube, n/N (%)“11/50 (22)”“6/26 (23)”
Respiratory therapy, n/N (%)“9/50 (18)”“2/26 (8)”
Race White, n/N (%)“65/72 (90)”“22/26 (85)”
Race other, n/N (%)“7/72 (10)”“4/26 (15)”
Region Europe, n/N (%)“11/72 (15)”“90/119 (76)”
Region North America, n/N (%)“61/72 (85)”“27/119 (23)”
Region South America, n/N (%)“0 (0)”“2/119 (2)”
Efficacy results
Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026
Population and comparator sourceDeaths, treated (%)Deaths, control (%)Hazard ratio (95% CI)P-value
Overall infantile, pooled comparator“9 (13.6%)”“42 (63.3%)”“0.162 (0.069, 0.380)”“<0.0001”
Early infantile, pooled comparator“6 (18.8%)”“23 (72.8%)”“0.109 (0.035, 0.333)”“<0.0001”
Late infantile, pooled comparator“3 (8.8%)”“18 (54.3%)”“0.148 (0.040, 0.546)”“0.0036”
With miglustat“2 (7.1%)”“12 (41.8%)”“0.097 (0.023, 0.406)”“0.0005”
Without miglustat“5 (21.7%)”“18 (79.9%)”“0.123 (0.036, 0.425)”“<0.0001”
French comparator“5 (9.8%)”“42 (82.1%)”“0.073 (0.023, 0.236)”“<0.0001”
NIH comparator“5 (15.2%)”“24 (71.2%)”“0.176 (0.060, 0.517)”“<0.0001”
YODA comparator“4 (11.4%)”“6 (17.9%)”“0.298 (0.082, 1.086)”“0.1168”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations of the integrated externally controlled survival analysis
  • Design: the comparison is with external controls. A statistical methods poster on the analysis states that externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies, and that target trial emulation identified four principal threats: prognostic factor confounding, post-baseline treatment confounding, immortal time bias, and temporal bias. Both the label analysis and the company analysis required each matched control to be alive at the treated participant's age at treatment initiation.
  • Label analysis: all 26 external control participants came from Study 1 and were weighted to a number of 36 against 36 treated participants. Matching used disease subtype, age of neurological symptom onset (±3 months), and baseline miglustat use; 58% of treated and 33% of control participants were male, median follow-up from the index age was 5.6 and 4.2 years, and index ages ranged from 1 to 19 years. The label states that safety and effectiveness in reducing mortality with neurological onset at 6 years of age or older has not been established.
  • Analysis with broader external controls: 72 treated participants were matched with 119 external controls drawn from 4 major disease databases or publications, and the poster states that comparability factors were not available from all sources.
  • Variation in the estimate: the hazard ratio differed by comparator source (French 0.113; NIH 0.449, 95% CI 0.214 to 0.946; YODA 0.381, 95% CI 0.128 to 1.137, P = 0.1426) and between data cuts (0.162 with 66 treated participants at the June 24, 2024 cutoff; 0.289 with 72 at the January 10, 2025 cutoff). The label analysis reported 0.45 (0.21, 0.95). The statistical methods poster reported that hazard ratio estimates across its prespecified sensitivity analyses remained consistent with the primary analysis.
  • Analysis plan: the YODA Project data request that proposed the external control analysis stated that “All planned statistical analyses are exploratory” and that no minimum sample size was determined a priori.

VTS301 parts A and B

Objective
Location and study date
Registry study dates and enrollment
FieldQuoted record
Study start (actual)“2015-10”
Primary completion (actual)“2018-03-28”
Study completion (actual)“2018-03-28”
Enrollment (actual)“56”
Results first posted“2023-02-22”
Study sites by country
CountryFacility
United States“University of Alabama at Birmingham”
United States“Children's Hospital of Orange County”
United States“University of California San Francisco”
United States“University of Colorado Denver”
United States“Shands Children's Hospital”
United States“Rush University Medical Center”
United States“Eunice Kennedy Shriver National Institute of Child Health and Human Development”
United States“Boston Children's Hospital”
United States“Montefiore Medical Center”
United States“University of North Carolina”
United States“Lehigh Valley Health Network”
United States“The Children's Hospital of Philadelphia”
United States“Dell Children's Medical Center of Central Texas”
United States“Multicare Institute for Research and Innovation”
Australia“The Prince of Wales Hospital”
Australia“Monash Medical Centre”
Australia“Royal Melbourne Hospital”
Australia“Royal Perth Hospital”
France“CHU Paris Est - Hospital d'Enfants Armand-Trousseau”
Germany“Katholisches Klinikim Bochum gGmbH”
Germany“Universitaetsklinikum Mainz”
Germany“Universitaetsklinikum Muenster”
New Zealand“Waikato Hospital”
Singapore“National University Hospital (Singapore) Pte, Ltd”
Spain“Hospital Universitario del Valle Hebron”
Turkey“Hacettepe University Medical Faculty”
Turkey“Gazi University Medical Faculty”
United Kingdom“Great Ormond Street Hospital”
United Kingdom“Birmingham Women's and Children's NHS Trust”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using the 4-Item NPC severity scale composite score as a co-primary endpoint
Inter-rater reliability of central NPC-SS scoring in this trial

“The objective of the study was to examine the inter-rater reliability of the NPC-SS in a Phase 2/3 clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Clinical data recorded at each study site were distributed to two independent blinded central raters to generate a severity score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The average ICCs for absolute agreement for the 4-item and 5-item scales, respectively, were ICC (3,2) = 0.95 [95% CI = 0.93, 0.97] and 0.96 [95% CI = 0.93, 0.97] for the multiple assessment, and ICC (3,1) = 0.91 [95% CI = 0.87, 0.94] and 0.92 [95% CI = 0.87, 0.94] for the single assessment (Supplemental Data, Table 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the NPC-SS 4-item composite score, the average kappa was 0.36 [95% CI= 0.31, 0.42], the average weighted kappa was 0.76 [95% CI= 0.73, 0.79], and the average percent agreement between raters was 40.9% (95% CI= 35.2, 46.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These results support the NPC-SS, including derived 4- and 5-item composite scores, as reliable measures for use in a clinical trial setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed for the co-primary endpoints
AnalysisSham controlAdrabetadex
4-item NPC-SS composite, participants analyzed“18”“38”
Participants analyzed for secondary endpoints
Outcome measureSham controlAdrabetadex
NPC-SS total score excluding hearing and ABR“18”“37”
Annualized rate of change (slope) of NPC-SS composite“14”“34”
Description of analysis sets
Results
Participant disposition
Participant flow in the ClinicalTrials.gov record
MilestonePart A adrabetadex 900 mgPart A adrabetadex 1200 mgPart A adrabetadex 1800 mgPart A shamPart B adrabetadex 900 mgPart B sham
Started“3”“3”“3”“3”“29”“15”
Completed“3”“3”“3”“3”“27”“14”
Not completed“0”“0”“0”“0”“2”“1”
Withdrawal by subject“0”“0”“0”“0”“2”“1”
Baseline characteristics
Baseline demographics of the intent-to-treat population in the ClinicalTrials.gov record
CharacteristicSham control (n = 18)Adrabetadex (n = 38)Total (n = 56)
Age, years, mean (SD)“11.7(5.10)”“12.7(5.64)”“12.4(5.45)”
Female“10”“16”“26”
Male“8”“22”“30”
White“16”“31”“47”
Asian“1”“4”“5”
Hispanic or Latino“3”“3”“6”
Baseline 4-item NPC-SS composite score
StatisticSham controlAdrabetadex
Baseline mean“8.1”“8.8”
Baseline standard deviation“4.27”“3.12”
Baseline weight, miglustat use, seizures, symptom duration, and total severity score
CharacteristicAdrabetadex (N=38)Sham control (N=18)
Weight (kg), mean (SD)“48.1 (25.27)”“40.2 (18.98)”
Miglustat use, n (%)“25 (66)”“9 (50)”
Seizures, n (%)“15 (39)”“5 (28)”
Duration of neurologic symptoms (years), mean (SD)“7.1 (4.15)”“5.9 (5.16)”
Baseline NPC-CSS total score (minus hearing/ABR), mean (SD)“17.8 (6.48)”“16.9 (8.16)”
Efficacy results
Co-primary endpoint: change in 4-item NPC-SS composite score at Week 52
StatisticSham control (n = 18)Adrabetadex (n = 38)
Change from baseline at Week 52, mean“-0.1”“0.0”
Change from baseline at Week 52, standard deviation“1.55”“2.45”
Co-primary endpoint: clinician CGIC at Week 52
CGIC categorySham control (n = 18)Adrabetadex (n = 38)
Markedly improved (1)“0”“0”
Moderately improved (2)“1”“5”
Minimally improved (3)“4”“9”
Unchanged (4)“9”“16”
Minimally worse (5)“2”“6”
Moderately worse (6)“2”“1”
Markedly worse (7)“0”“1”
Secondary endpoints reported in the ClinicalTrials.gov results
Outcome measureSham controlAdrabetadex
NPC-SS total score excluding hearing and ABR, change at Week 52, mean (SD)“-0.74(2.357)”“-0.34(4.226)”
Responders on NPC-SS total score excluding hearing and ABR at Week 52, participants“13”“22”
Participants who qualified for the rescue option“2”“2”
Time to one-point worsening in NPC-SS composite score, median days (95% CI)“118 (55 to 364)”“169 (70 to 278)”
9-Hole Peg Test, change at Week 52, seconds, mean (SD)“-1.49(15.958)”“-1.79(34.760)”
Annualized rate of change (slope) of NPC-SS composite, mean (SD)“-0.05(1.640)”“0.08(2.441)”
Timed Up and Go test and total NPC-SS including hearing
Outcome measureSham controlAdrabetadex
Timed Up and Go, change at Week 52, seconds, mean“0.86”“2.70”
Timed Up and Go, change at Week 52, seconds, SD“19.232”“9.633”
Total NPC-SS with hearing and ABR, change at Week 52, mean“0.000”“0.75”
Total NPC-SS with hearing and ABR, change at Week 52, SD“1.000”“4.500”
Change in each NPC-SS domain at Week 52
Domain, change from baseline at Week 52Sham control, meanSham control, SDAdrabetadex, meanAdrabetadex, SD
Ambulation“0.00”“0.679”“0.06”“1.434”
Fine motor“0.07”“0.917”“0.24”“1.103”
Cognition“-0.14”“0.663”“0.06”“0.919”
Swallowing“0.00”“1.109”“-0.29”“1.360”
Memory“0.00”“0.784”“0.18”“1.218”
Speech“0.14”“0.663”“-0.18”“0.673”
Eye movement“0.00”“0.679”“-0.06”“0.547”
Hearing“-0.22”“1.302”“1.14”“1.236”
Seizures“-0.50”“1.286”“-0.06”“0.952”
Health-related quality of life and patient-reported outcomes
EQ-5D-3L visual analog scale at baseline and Week 52
Time pointSham control meanSham control SDAdrabetadex meanAdrabetadex SD
Baseline“71.9”“16.28”“68.3”“19.97”
Week 52“73.2”“13.04”“75.7”“19.00”
Safety results
Deaths, serious adverse events, and other adverse events by arm
EventPart A adrabetadex 900 mgPart A adrabetadex 1200 mgPart A adrabetadex 1800 mgPart A shamPart B adrabetadex 900 mgPart B sham
All-cause mortality“0/3 (0.00%)”“0/3 (0.00%)”“1/3 (33.33%)”“0/3 (0.00%)”“0/29 (0.00%)”“1/15 (6.67%)”
Any serious adverse event“1/3 (33.33%)”“0/3 (0.00%)”“2/3 (66.67%)”“0/3 (0.00%)”“16/29 (55.17%)”“3/15 (20.00%)”
Any other (non-serious) adverse event“3/3 (100.00%)”“3/3 (100.00%)”“3/3 (100.00%)”“3/3 (100.00%)”“28/29 (96.55%)”“14/15 (93.33%)”
Serious adverse events of hearing, seizure, and aspiration in Part B
Serious adverse eventPart B adrabetadex 900 mgPart B sham
Deafness“3/29 (10.34%)”“0/15 (0.00%)”
Hearing impaired“3/29 (10.34%)”“1/15 (6.67%)”
Seizure“3/29 (10.34%)”“1/15 (6.67%)”
Aspiration“2/29 (6.90%)”“1/15 (6.67%)”
Pneumonia aspiration“3/29 (10.34%)”“0/15 (0.00%)”
Study limitations
Summary: design limitations of Parts A and B
  • Control and observed progression: Parts A and B compared intrathecal VTS-270 with a sham procedure of 1 to 2 small needle pricks on the lower back with no lumbar puncture. At Week 52 the mean change from baseline in the NPC-SS composite score was -0.1 (SD 1.55) in the sham group (n = 18) and 0.0 (SD 2.45) in the adrabetadex group (n = 38). The company stated that “Neither the VTS-270 nor the placebo arm showed disease progression”, and a data request summary states that the trial failed to show benefit “as the sham group had little progression” and that sham-controlled trials in NPC “are highly challenging due to variability of the disease”.
  • Blinding: the participant, outcomes assessor, care provider, and investigator were blinded. The hearing rating was excluded from the efficacy score because the drug can cause hearing loss and “hearing information might have unblinded the NPC-SS raters to treatment status”. NPC-SS scores were generated by two central raters, which the inter-rater reliability study lists as a limitation.
  • Sample size: the sample size was based on the potential number of available subjects for this ultra-rare disorder. The plan of approximately 51 subjects gave the ANCOVA 79% power under assumed 52-week increases of 0 to 0.2 points with VTS-270 and 1.6 to 1.9 points with sham. The statistical analysis plan states that 54 subjects were randomized; the prescribing information states that Parts A and B enrolled 56 treatment-naïve participants.
  • Randomization ratio: one publication states that Part A randomized 12 subjects 1:1:1:1 to three dose levels or sham, and protocol amendment 15 states a 3:1 ratio in Part A. Both state a 2:1 ratio in Part B.
  • Analysis sets: the registry analyzed 38 adrabetadex and 18 sham participants for the co-primary NPC-SS composite endpoint and 34 and 14 for the annualized slope. The prescribing information describes 32 participants who received up to 900 mg and 18 in the sham-control group. The statistical analysis plan restricts the modified intent-to-treat population to subjects who received at least one dose of 900 mg of VTS-270 or sham control, and the registry defines it as all randomized participants who received at least one treatment (sham or adrabetadex). The statistical analysis plan also changed the protocol's list of key secondary endpoints.
  • Early exit: Part B participants with significant disease progression after 26 weeks or more could leave the blinded trial early and enter Part C; 2 sham and 2 adrabetadex participants qualified for this rescue option.
  • Concomitant miglustat: randomization in Part B was stratified by miglustat use and baseline NPC-SS level, but the statistical analyses were not stratified. At baseline, 25 (66%) adrabetadex and 9 (50%) sham participants used miglustat. A post hoc analysis reported that subjects receiving miglustat, with or without adrabetadex, showed evidence of disease stabilization, while subjects receiving adrabetadex without miglustat showed disease worsening comparable to sham subjects not on miglustat.
  • Biomarkers: cerebrospinal fluid was collected only from subjects receiving study drug; sham-control subjects provided urine and plasma. The post hoc biomarker study of 34 participants tested within-group changes with the Wilcoxon signed-rank test, with nominal significance at P<0.05 without adjustment for multiplicity.
  • Sponsor statements: the company stated that it was evaluating this portion of the study “in order to ensure the data was properly captured and of the highest quality”. A community update stated that a manuscript summarizing the data and experience from the VTS-301 trial was being prepared.

VTS301 part C

Objective
Location and study date
Registry study dates and enrollment
FieldQuoted record
Study start (actual)“2015-12-23”
Primary completion (actual)“2022-04-11”
Study completion (actual)“2022-04-11”
Enrollment (actual)“66”
Results first posted“2023-08-29”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by entry group
GroupParticipants analyzed
Treatment naive“18”
Previously treated in phase I“13”
Previously treated in Part A/B“35”
Total“66”
Description of analysis sets
Results
Participant disposition
Participant flow and reasons for not completing
Milestone or reasonTreatment naivePreviously treated in phase IPreviously treated in Part A/B
Started“18”“13”“35”
Completed“0”“0”“0”
Not completed“18”“13”“35”
Adverse event“1”“0”“1”
Death“0”“0”“1”
Investigator's decision“0”“0”“1”
Lost to follow-up“1”“0”“0”
Termination by sponsor or regulatory authorities“8”“4”“13”
Transferred to EAP following study termination“0”“0”“1”
Transferred to Expanded Access Program“1”“0”“0”
Transferred to OLEX program“3”“0”“5”
Withdrawal by subject“4”“9”“13”
Recorded reason the study stopped
Baseline characteristics
Baseline demographics by entry group
CharacteristicTreatment naive (n = 18)Previously treated in phase I (n = 13)Previously treated in Part A/B (n = 35)Total (n = 66)
Age, years, mean (SD)“13.2(5.07)”“17.5(6.16)”“14.1(5.60)”“14.5(5.70)”
Female“10”“7”“15”“32”
Male“8”“6”“20”“34”
White“16”“13”“29”“58”
Hispanic or Latino“3”“1”“2”“6”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Primary outcome: participants with TEAEs and SAEs
OutcomeTreatment naive (n = 18)Previously treated in phase I (n = 13)Previously treated in Part A/B (n = 35)
Any TEAEs“18”“13”“34”
SAEs“9”“7”“20”
Deaths and serious adverse events
VTS-270-302 safety
OutcomeAdrabetadex (n = 2)
All TEAEs, participants“2”
SAEs, participants“0”
All-cause mortality“0/2 (0.00%)”
Study limitations
Summary: design limitations of Part C
  • Control and blinding: Part C was an open-label extension in which all participants received study drug, and the sponsor gave it a separate registration because of its different study design.
  • Mixed population and dosing: Part C enrolled 66 participants, comprising 35 LEMBAZ-treated participants from Parts A and B, 18 treatment-naïve participants, and 13 LEMBAZ-treated patients from Trial 2. The dose could be adjusted between 400 mg and 900 mg at the investigator's discretion, and rollover participants from Study 13-CH-0001 received an amended dose and/or regimen.
  • Missing efficacy collection: the planned efficacy endpoints included the NPC-SS composite and the EQ-5D-3L. Following a determination of a negative benefit/risk balance on 20 January 2021, the objective of Part C was changed to longer-term safety and tolerability only, and efficacy endpoints after 20 January 2021 were not reported.
  • Early termination: the sponsor discontinued the development program and terminated Part C. No participant completed the study (0 of 18 treatment-naive, 0 of 13 previously treated in phase I, and 0 of 35 previously treated in Part A/B); termination by sponsor or regulatory authorities accounted for 8, 4, and 13 participants and withdrawal by subject for 4, 9, and 13.
  • Selective continuation: after 21 June 2021, only subjects who appeared to be benefiting in the investigator's assessment, and who understood that no significant differences were seen between adrabetadex and sham on any efficacy measure in the randomized trial, could continue treatment.
  • Substudies: the planned European plasma and CSF pharmacokinetic substudy of administration through the device was not conducted because no subjects consented.
  • VTS-270-302 continuation study: planned for approximately 7 subjects, it enrolled 2, was terminated early by the sponsor, did not perform efficacy assessments or analyze existing efficacy data, and reported no baseline data to maintain participant confidentiality.

VTS-270-001

Objective
Location and study date
Registry study dates
FieldRegistry record
Study start (actual)“2018-06-18”
Primary completion (actual)“2021-11-02”
Study completion (actual)“2021-11-02”
First posted“2018-08-23”
Results first posted“2024-01-17”
Study sites in the United States
FacilityLocation
“University of Arkansas System”“Little Rock, Arkansas, United States, 72205”
“Loma Linda University Health System”“Loma Linda, California, United States, 92354”
“Children's Hospital Los Angeles”“Los Angeles, California, United States, 90027”
“Children's Hospital of Orange County”“Orange, California, United States, 92868”
“Children's Hospital Colorado”“Aurora, Colorado, United States, 80045”
“Children's National Hospital”“Washington D.C., District of Columbia, United States, 20010”
“Rare Disease Research, LLC”“Atlanta, Georgia, United States, 30318”
“Rush University Medical Center”“Chicago, Illinois, United States, 60612”
“Gillette Children's Specialty Healthcare”“Saint Paul, Minnesota, United States, 55101”
“Children's Specialty Center of Nevada”“Las Vegas, Nevada, United States, 89109”
“NYU Langone Medical Center”“New York, New York, United States, 10017”
“Cincinnati Children's Hospital Medical Center”“Cincinnati, Ohio, United States, 45229”
“Oregon Health & Science University”“Portland, Oregon, United States, 97239”
“The Children's Hospital at TriStar Centennial”“Nashville, Tennessee, United States, 37203”
“Vanderbilt University Medical Center”“Nashville, Tennessee, United States, 37232”
“Dell Children's Medical Center of Central Texas”“Austin, Texas, United States, 78723”
“Carilion Medical Center, Carilion Clinic”“Roanoke, Virginia, United States, 24014”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment and participants analyzed by group
FieldTreatment naivePreviously treatedTotal
Overall number of baseline participants“9”“18”“27”
Description of analysis sets
Registry analysis population for baseline, outcome, and adverse event data
FieldRegistry record
Baseline, outcome, and adverse event analysis population“All enrolled participants”
Results
Participant disposition
Registry participant flow and reasons for not completing
Milestone or reasonTreatment naivePreviously treated
Started“9”“18”
Received at least 1 dose of study drug“9”“18”
Completed“1”“2”
Not completed“8”“16”
Adverse event“1”“0”
Lack of efficacy“0”“1”
Other than specified“3”“2”
Physician decision“0”“1”
Study terminated by sponsor“2”“10”
Withdrawal by subject“2”“2”
Baseline characteristics
Registry baseline demographics
CharacteristicTreatment naive (n=9)Previously treated (n=18)Total (n=27)
Age, mean (SD), years“12.33(8.718)”“17.94(13.705)”“16.07(12.388)”
Female, participants“4”“7”“11”
Male, participants“5”“11”“16”
Hispanic or Latino, participants“1”“0”“1”
White, participants“7”“17”“24”
Black or African American, participants“0”“1”“1”
Race unknown or not reported, participants“2”“0”“2”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Primary outcome: participants with treatment-emergent and serious adverse events
OutcomeTreatment naive (n=9)Previously treated (n=18)
All TEAEs, participants“9”“17”
SAEs, participants“5”“9”
All-cause mortality and serious adverse events by preferred term
Selected other (non-serious) adverse events reported at a 5% frequency threshold
Study limitations
Summary: design limitations of VTS-270-001
  • Control and blinding: VTS-270-001 was a non-randomized, open-label, single-arm trial with masking recorded as none; the protocol used no control product and no data monitoring committee.
  • Sample size and population: the protocol anticipated approximately 60 subjects from 30 sites, and no new subjects could enroll after 20 January 2021. The trial enrolled 27 participants (9 treatment-naïve and 18 previously treated through the expanded access program) aged 4 to 43 years. Treatment-naïve participants started at 400 mg, previously treated participants continued at their current stable dosage, and dose increases stopped as of Amendment 2 (21 April 2021).
  • Missing efficacy collection: under the amended protocol, efficacy assessments (NPC-SS and clinician CGIC) and the EQ-5D-3L were not collected or analyzed, and auditory brainstem responses were not collected as of 20 January 2021.
  • Analysis: data were summarized with descriptive statistics, with no hypothesis testing and no imputation of missing data.
  • Early termination: the trial was terminated early when the sponsor determined that the benefit-risk profile of adrabetadex was not favorable, and treatment was allowed to continue up to 20 October 2021. Of 27 participants, 1 treatment-naive and 2 previously treated participants completed; study termination by the sponsor accounted for 2 and 10 participants. After 21 June 2021, continuation required the investigator to assess that the subject was benefiting from treatment.
  • Sponsor statements: the protocol states that a comprehensive evaluation of all available clinical data “shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC” and that “the benefit/risk balance is negative.”

Expanded access program

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using rescored 4-domain NPC clinical severity scale as the disease progression outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled, December 2021
FieldDashboard
Current patients enrolled in Expanded Access Program“50 patients”
Description of analysis sets
Results
Participant disposition
Time since first dose and discontinuations in the expanded access program
MeasureAll EAP (n=86)
Time since first treatment dose, median [IQR], months“52.8 [15.4, 74.2]”
TEAE leading to discontinuation, n (%)“3 (3.5)”
TEAE leading to death, n (%)“6 (7.0)”
Baseline characteristics
Baseline characteristics of all expanded access participants
CharacteristicAll EAP (N=86)
Neurological onset <2 years, n (%)“26 (30.2)”
Neurological onset 2 to 6 years, n (%)“23 (26.7)”
Neurological onset ≥6 years, n (%)“29 (33.7)”
Age at onset missing, n (%)“8 (9.3)”
Age at neurological symptom onset, median (Q1, Q3), years (n=78)“3.5 (1.5, 7.0)”
Age at adrabetadex treatment start, median (Q1, Q3), years (n=78)“8.0 (3.0, 20.0)”
Male, n (%)“51 (59.3)”
Female, n (%)“34 (39.5)”
White, n (%)“76 (88.4)”
Miglustat use at baseline, yes, n (%)“33 (38.4)”
Miglustat use at baseline, no, n (%)“46 (53.5)”
Baseline characteristics of treated participants with infantile onset in the disease burden analysis
CharacteristicOverall (N=76)
Neurological onset <2 years, n (%)“33 (43.4)”
Neurological onset 2 to <6 years, n (%)“43 (56.6)”
Age at neurological symptom onset, mean (SD), years“2.5 (1.56)”
Age at adrabetadex treatment start, mean (SD), years“7.7 (5.56)”
Age at adrabetadex treatment start, median (Q1, Q3), years“6.2 (3.2, 10.8)”
Male, n (%)“41 (53.9)”
White, n (%)“66 (86.8)”
Baseline R4DNPCCSS, mean (SD)“7.2 (5.06)”
Baseline R4DNPCCSS, median (Q1, Q3)“7.0 (3.0, 10.0)”
Baseline characteristics by time from onset to treatment
CharacteristicTreatment initiation <1 year from onset (n=9)Treatment initiation ≥1 year from onset (n=16)
Age at neurological symptom onset, mean (SD), years“2.11 (1.563)”“2.65 (1.494)”
Age at adrabetadex treatment start, mean (SD), years“2.70 (1.614)”“7.15 (3.838)”
Duration from onset to treatment, mean (SD), years“0.59 (0.324)”“4.50 (3.308)”
Miglustat use at baseline, yes, n (%)“1 (11.1)”“9 (56.3)”
Baseline R4DNPCCSS, median (Q1, Q3)“1.50 (0.50, 2.50)”“5.00 (2.00, 10.00)”
Duration of treatment exposure, mean (SD), weeks“348.37 (54.297)”“397.23 (93.427)”
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events in the expanded access program by combination therapy group
MeasureAdrabetadex first, adrabetadex-only period (n=28)Any combination exposure, combination period (n=33)No combination after adrabetadex (n=53)All EAP (n=86)
With ≥1 TEAE (any grade), n (%)“28 (100)”“23 (69.7)”“48 (90.6)”“81 (94.2)”
Leading to death, n (%)“0”“1 (3.0)”“5 (9.4)”“6 (7.0)”
Serious AEs, n (%)“13 (46.4)”“8 (24.2)”“24 (45.3)”“41 (47.7)”
Grade ≥3, n (%)“9 (32.1)”“6 (18.2)”“21 (39.6)”“33 (38.4)”
TEAEs of interest, n (%)“22 (78.6)”“9 (27.3)”“35 (66.0)”“62 (72.1)”
Ataxia, n (%)“10 (35.7)”“5 (15.2)”“23 (43.4)”“37 (43.0)”
Fatigue, n (%)“17 (60.7)”“7 (21.2)”“25 (47.2)”“47 (54.7)”
Hearing impairment, n (%)“10 (35.7)”“2 (6.1)”“15 (28.3)”“26 (30.2)”
Hearing loss, post-dose ataxia and tiredness, and lumbar puncture events in the first three expanded access patients
Study limitations
Summary: design limitations of the expanded access program analyses
  • Control and setting: the original report of three patients names as limitations “the lack of a control group” and treatment through an expanded access protocol with likely more confounding changes from optimizing support and other treatments than in a clinical trial. Enrollment required that participants be ineligible for all currently enrolling clinical trials.
  • Population counts: the prescribing information describes 85 participants (71 treatment-naïve and 14 previously treated) with a mean (SD) treatment duration of 44 (32) months.
  • Dosing: doses started at 200 mg or 400 mg based on age, with titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.
  • External comparison and analysis sets: the survival analysis by baseline disease burden compared 80 adrabetadex-treated participants with I-NPC (neurological onset <6 years) from clinical studies or the expanded access program with an untreated cohort of 44 from the NIH natural history study. Four treated participants without a baseline R4DNPCCSS score were excluded, leaving 76. Baseline was the last observation before the first dose for treated participants and the first available observation for the untreated cohort, and the authors state that “no matching procedure was performed between treated and untreated participants.”
  • Prompt versus delayed treatment: the analysis included only participants with onset <6 years of age who had sustained treatment for at least 5 years, 9 with treatment initiation <1 year and 16 with initiation ≥1 year from onset, and miglustat use at baseline was 1 (11.1%) and 9 (56.3%), respectively. The company compared progression in these 25 participants with published natural history data.
  • Combination therapy analysis: participants exposed to combination therapy had a shorter time since first treatment dose, as most started those therapies when they became commercially available at the end of 2024. Safety data were collected only while participants were in the study and receiving adrabetadex, and were not available for other NPC therapies received before enrollment.
  • Concomitant miglustat: all three patients in the original report went on miglustat at the same age as diagnosis, and its authors state that an effect of miglustat or of the combination on progression cannot be ruled out. In the CSF neuron-specific enolase study, most participants receiving intrathecal HPβCD were also on miglustat, which the authors state makes it challenging to attribute the decrease to HPβCD alone.
  • Sample size: the long-term 24(S)-hydroxycholesterol study included 10 individuals, and its authors state that its conclusions are limited by its small size; the CSF neuron-specific enolase study used a subset of ten expanded access participants.

NIH phase 1-2a trial

Objective
Location and study date
Registry dates, enrollment, and single study location
Study design
Eligibility criteria
Exclusion criteria: severe or asymptomatic disease, prior cyclodextrin, and conditions affecting lumbar puncture or audiology

“Severe manifestations of NPC1 that would interfere with the patient's ability to comply with the requirements of this protocol.” (opens the source at this quote in a new tab)

“Neurologically asymptomatic patients.” (opens the source at this quote in a new tab)

“Patients who have received any form of cyclodextrin in an attempt to treat NPC1. Treatment with another drug preparation for another medical indication that contains cyclodextrin as an excipient, will not exclude a patient.” (opens the source at this quote in a new tab)

“Spinal deformity that would impact the ability to perform a lumbar puncture” (opens the source at this quote in a new tab)

“Contraindication for anesthesia.” (opens the source at this quote in a new tab)

“Patients unable to complete a behavioral audiologic evaluation including pure-tone threshold assessment (500 Hz to 8000 Hz) to monitor for ototoxicity and for whom otoacoustic emissions (OAEs) cannot be reliably obtained at baseline.” (opens the source at this quote in a new tab)

“Patients with ongoing seizures, that are not stable in frequency, type or duration over a 2 month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using plasma 24(S)-Hydroxycholesterol area under the curve as the primary endpoint
Registered primary and secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment of 14 participants
FieldQuoted record
Enrollment (actual)“14”
Phase“Phase 1”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary: design limitations of the NIH phase 1-2a trial
  • Control and external comparison: the trial was a non-randomized, open-label, single-center dose escalation study. The authors state that it “relies on a historical comparison group, and is not a randomized, placebo-controlled trial.” Efficacy compared NSS progression in the 14 NIH participants with a historical cohort of 21 participants from a natural history study, selected for two or more assessments within 25 months and an age of 4 to 24 years. Natural history participants were on average younger and had lower NSS at baseline (mean total NSS 14.5 ± 9.7 versus 19.3 ± 7.5), differences the authors report as not significant.
  • Analysis: the clinical efficacy data come from an ad-hoc analysis using a post hoc mixed model repeated measures approach. No formal sample size calculation was made, confidence intervals were not estimated given the small sample size, and the responder analysis used Fisher's exact test with a nominal p-value of 0.05.
  • Dose escalation: the authors state that the dose escalation design limits the ability to establish dose-response correlations. The publication describes monthly doses of 50 to 1200 mg in the 14 NIH participants and every-two-week dosing in three additional participants at Rush University Medical Center; the prescribing information describes doses of 200 to 1,200 mg once monthly, regimens it does not recommend.
  • Unequal follow-up and measurement: NSS data for three participants (CDA102, CDA113, and CDA114) were obtained at 12 months and for the others at 18 or 19 months. Behavioral audiograms could be obtained for 12 of 14 participants.
  • Concomitant miglustat: 12 (86%) treated and 16 (76%) natural history participants used miglustat. In the 36-month neuropsychological analysis, 11 of 14 participants took miglustat at baseline and throughout, and the small number not taking it prevented assessment of its confounding effect.
  • Neuropsychological follow-up: the analysis had no comparison or historical control group, was descriptive because the study was not designed to target neuropsychological efficacy, had no a priori power calculation, and had a sample below the n ≈ 30 suggested for the standard errors of the fixed effect. Fewer than 10 WRAML observations were available at most timepoints.
  • Confirmation: the authors state that data from a randomized, sham-controlled phase 2b/3 study would be needed to confirm the results.